{
  "docId": "019de072-4729-7396-8f8e-eb3955e66e61",
  "docSlug": "7286daabf487d40c2a70ede12061c49a",
  "documentTitle": "Apexigen | SPAC Presentation Deck | 28 slides",
  "authorId": "apexigen",
  "authorName": "Apexigen",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 28,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4729-7396-8f8e-eb3955e66e61/18",
  "deckHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61",
  "deckJsonHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61.json",
  "deckAnchorHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.66,
        "y": 0.25
      },
      "kind": "list",
      "text": "Multiple Upcoming Phase 2 Data Readouts. Preliminary data in 2022/2023, seeking FDA Type C meeting for melanoma path.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "476e811b-10a0-4c5a-9937-7729d2fad4fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.06,
        "y": 0.25
      },
      "kind": "list",
      "text": "Sotigalimab is Potentially the First-in-Class and Best-in-Class CD40 Agonist Antibody. Single-agent anti-tumor effects, broad applicability, well tolerated, other potential indications.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a55e8296-9392-4230-a147-def23546c100",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.36,
        "y": 0.25
      },
      "kind": "list",
      "text": "Therapeutic Effect Observed in Several Indications. Clinical data demonstrate anti-tumor effect, potential for multiple accelerated approval pathways.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8dc8bf8-8f55-4157-9a7b-2ed4ca98966c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Summary of Sotigalimab Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6390e2a2-1114-4c63-ba1a-133affb23daf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "ace8bbbb-5626-4a71-995a-7859c55fd9a2",
      "evidence": "list/bullet: Sotigalimab is Potentially the First-in-Class and Best-in-Class CD40 Agonist Antibody.",
      "confidence": 0.8
    },
    {
      "name": "Storytelling: the three headline reasons",
      "slug": "three-reasons",
      "agent": "storyteller",
      "layer": "slide",
      "matchId": "63e173e4-3c61-446f-8fde-f0db3ba8bf04",
      "evidence": "list/bullet: Therapeutic Effect Observed in Several Indications. list/bullet: Multiple Upcoming Phase 2 Data Readouts.",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}